$51.6 Million is the total value of Stonepine Capital Management, LLC's 13 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 74.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $13,972,000 | +57.2% | 2,739,641 | +6.0% | 27.06% | +187.9% |
| LGND | Sell | LIGAND PHARMACEUTICALS | $10,336,000 | -11.7% | 92,407 | -42.6% | 20.02% | +61.8% |
| CTIC | Sell | CTI BIOPHARMA CORP | $4,719,000 | -20.2% | 4,068,191 | -36.7% | 9.14% | +46.1% |
| DMAC | Sell | DIAMEDICA THERAPEUTICS INC | $4,632,000 | +100.4% | 668,430 | -19.0% | 8.97% | +267.1% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $3,214,000 | -27.8% | 547,541 | -46.3% | 6.22% | +32.2% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $3,046,000 | -13.4% | 4,447,026 | -5.2% | 5.90% | +58.6% |
| XOMA | Sell | XOMA CORP | $2,968,000 | -30.1% | 150,213 | -28.0% | 5.75% | +28.1% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $2,367,000 | -26.8% | 1,447,765 | -14.0% | 4.58% | +34.1% |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $2,253,000 | -31.6% | 676,592 | -25.5% | 4.36% | +25.2% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $1,940,000 | -42.3% | 757,704 | -34.8% | 3.76% | +5.7% |
| CERC | New | CERECOR INC | $1,171,000 | – | 450,500 | +100.0% | 2.27% | – |
| PROG | New | PROGENITY INC | $865,000 | – | 96,135 | +100.0% | 1.68% | – |
| BBI | New | BRICKELL BIOTECH INC | $147,000 | – | 146,739 | +100.0% | 0.28% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -10,000 | -100.0% | -0.02% | – |
| HTGM | Exit | HTG MOLECULAR DIAGNOSTICS | $0 | – | -992,641 | -100.0% | -0.34% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -151,189 | -100.0% | -0.38% | – |
| Exit | INTERPACE BIOSCIENCES INC | $0 | – | -178,295 | -100.0% | -0.98% | – | |
| BXRX | Exit | BAUDAX BIO INC | $0 | – | -610,200 | -100.0% | -1.60% | – |
| AGTC | Exit | APPLIED GENETIC TECHNOLOGIES | $0 | – | -586,969 | -100.0% | -2.04% | – |
| SPNE | Exit | SEASPINE HOLDINGS CORP | $0 | – | -253,131 | -100.0% | -2.19% | – |
| CHMA | Exit | CHIASMA INC | $0 | – | -744,134 | -100.0% | -2.87% | – |
| BDSI | Exit | BIODELIVERY SCIENCES INTL | $0 | – | -755,000 | -100.0% | -3.03% | – |
| Exit | AEGERION PHARMACEUTICALSAEGR 5 04/01/25note 5.000% 4/0 | $0 | – | -3,037,627 | -100.0% | -3.05% | – | |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -1,302,981 | -100.0% | -3.42% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -822,960 | -100.0% | -3.61% | – |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -374,431 | -100.0% | -3.67% | – |
| OPNT | Exit | OPIANT PHARMACEUTICALS INC | $0 | – | -380,948 | -100.0% | -3.86% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -886,632 | -100.0% | -4.54% | – |
| AFMD | Exit | AFFIMED NV | $0 | – | -3,000,000 | -100.0% | -5.01% | – |
| AMRN | Exit | AMARIN CORP PLC -ADRspons adr new | $0 | – | -1,313,100 | -100.0% | -5.55% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.